MIRA Pharmaceuticals (NASDAQ:MIRA) Trading Up 2.1% - Here's What Happened

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA - Get Free Report) rose 2.1% during trading on Wednesday . The company traded as high as $1.55 and last traded at $1.48. Approximately 418,018 shares changed hands during trading, an increase of 125% from the average daily volume of 185,498 shares. The stock had previously closed at $1.45.Get MIRA Pharmaceuticals alerts:Wall Street Analysts Forecast GrowthA number of brokerages recently weighed in on MIRA. Wall Street Zen downgraded shares of MIRA Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday, November 22nd. Weiss Ratings reiterated a "sell (d-)" rating on shares of MIRA Pharmaceuticals in a research note on Wednesday, December 10th. One analyst has rated the stock with a Sell rating, According to MarketBeat, MIRA Pharmaceuticals has a consensus rating of "Sell".Check Out Our Latest Report on MIRA PharmaceuticalsMIRA Pharmaceuticals Stock Up 2.1%The stock has a market cap of $61.98 million, a P/E ratio of -0.97 and a beta of 1.79. The business's 50-day simple moving average is $1.47 and its two-hundred day simple moving average is $1.42. MIRA Pharmaceuticals (NASDAQ:MIRA - Get Free Report) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($1.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($1.07). Analysts anticipate that MIRA Pharmaceuticals, Inc. will post -0.6 earnings per share for the current fiscal year. Institutional Investors Weigh In On MIRA PharmaceuticalsSeveral institutional investors have recently made changes to their positions in MIRA. First American Bank grew its position in shares of MIRA Pharmaceuticals by 150.0% in the third quarter. First American Bank now owns 50,000 shares of the company's stock valued at $68,000 after purchasing an additional 30,000 shares in the last quarter. Two Sigma Investments LP boosted its stake in MIRA Pharmaceuticals by 129.8% in the 3rd quarter. Two Sigma Investments LP now owns 45,703 shares of the company's stock worth $62,000 after purchasing an additional 25,816 shares during the period. International Assets Investment Management LLC purchased a new position in MIRA Pharmaceuticals during the 2nd quarter valued at about $42,000. Creative Planning purchased a new position in MIRA Pharmaceuticals during the 2nd quarter valued at about $27,000. Finally, XTX Topco Ltd bought a new stake in shares of MIRA Pharmaceuticals during the second quarter valued at about $26,000. Hedge funds and other institutional investors own 35.16% of the company's stock. MIRA Pharmaceuticals Company Profile (Get Free Report)MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.Featured ArticlesFive stocks we like better than MIRA PharmaceuticalsIndustrial Products Stocks Investing Post 35% Surge, Analysts Eye More Upside in Copper Giant FreeportWhat Are the FAANG Stocks and Are They Good Investments?Why a SpaceX IPO Could Be a Major Catalyst for GOOGL StockWhat is the FTSE 100 index? Can Upwork Maintain Its Comeback? Reasons to Be Bullish and BearishThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in MIRA Pharmaceuticals Right Now?Before you consider MIRA Pharmaceuticals, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MIRA Pharmaceuticals wasn't on the list.While MIRA Pharmaceuticals currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here